Non-hydroxamate 5-phenylpyrimidine-2,4,6-trione derivatives as selective inhibitors of tumor necrosis factor-α converting enzyme

Bioorganic and Medicinal Chemistry Letters

Volumn 15, Issue 12, 2005, Pages 2970-2973

  Duan, James J W ^a   Lu, Zhonghui ^a   Wasserman, Zelda R ^a   Liu, Rui Qin ^a   Covington, Maryanne B ^a   Decicco, Carl P ^a  

^a BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGGRECANASE; COLLAGENASE 3; GELATINASE A; HYDROXAMIC ACID; INTERSTITIAL COLLAGENASE; PHENYL GROUP; PYRIMIDINE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR;

ARTICLE; DRUG SELECTIVITY; ENZYME ASSAY; ENZYME INHIBITION; IC 50;

ADAM PROTEINS; ANIMALS; ENDOPEPTIDASES; HYDROXAMIC ACIDS; MATRIX METALLOPROTEINASES; METALLOENDOPEPTIDASES; MOLECULAR STRUCTURE; PROTEASE INHIBITORS; PYRIMIDINES; STRUCTURE-ACTIVITY RELATIONSHIP; SWINE;

SUIDAE;

EID: 19944376150     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2005.04.039     Document Type: Article

References (20)

1. M.H.A. Bemelmans, L.J.H. van Tits, and W.A. Buurman Crit. Rev. Immunol. 16 1996 1
2. R.C. Newton, and C.P. Decicco J. Med. Chem. 42 1999 2295
3. M.L. Moss, J.M. White, M.H. Lambert, and R.C. Andrews Drug Discovery Today 6 2001 417
4. R.A. Black Int. J. Biochem. Cell Biol. 34 2002 1
5. For a recent review of TACE inhibitors, see: J.S. Skotnicki, and J.I. Levin Annu. Rep. Med. Chem. 38 2003 153
6. J.J.-W. Duan, L. Chen, Z.R. Wasserman, Z. Lu, R.-Q. Liu, M.B. Covington, M. Qian, K.D. Hardman, R.L. Magolda, R.C. Newton, D.D. Christ, R.R. Wexler, and C.P. Decicco J. Med. Chem. 45 2002 4954
7. Z.R. Wasserman, J.J.-W. Duan, M.E. Voss, C.-B. Xue, R.J. Cherney, D.J. Nelson, K.D. Hardman, and C.P. Decicco Chem. Biol. 10 2003 215
8. R.J. Cherney, J.J.-W. Duan, M.E. Voss, L. Chen, L. Wang, D.T. Meyer, Z.R. Wasserman, K.D. Hardman, R.-Q. Liu, M.B. Covington, M. Qian, S. Mandlekar, D.D. Christ, J.M. Trzaskos, R.C. Newton, R.L. Magolda, R.R. Wexler, and C.P. Decicco J. Med. Chem. 46 2003 1811
9. J.J.-W. Duan, Z. Lu, C.-B. Xue, X. He, J.L. Seng, J.J. Roderick, Z.R. Wasserman, R.-Q. Liu, M.B. Covington, R.L. Magolda, R.C. Newton, J.M. Trzaskos, and C.P. Decicco Bioorg. Med. Chem. Lett. 13 2003 2035
10. For a review of MMP inhibitors, see: J.W. Skiles, N.C. Gonnella, and A.Y. Jeng Curr. Med. Chem. 8 2001 425
11. L.H. Foley, R. Palermo, O. Dunten, and P. Wang Bioorg. Med. Chem. Lett. 11 2001 969
12. F. Grams, H. Brandstetter, S. D'Alo, D. Geppert, H.-W. Krell, H. Leinery, V. Livi, E. Menta, A. Oliva, and G. Zimmermann Biol. Chem. 382 2001 1277
13. P. Dunten, U. Kammlott, R. Crowther, W. Levin, L.H. Foley, P. Wang, and R. Palermo Protein Sci. 10 2001 923
14. H. Brandstetter, F. Grams, D. Glitz, A. Lang, R. Huber, W. Bode, H.-W. Krell, and R.A. Engh J. Biol. Chem. 276 2001 17405
15. F. Grams, H. Brandstetter, R.A. Engh, D. Glitz, H.-W. Krell, V. Livi, E. Menta, L. Moroder, J.C.D. Muller, E.G. Roedern, and G. Zimmermann N.J. Clendeninn K. Appelt Matrix Metalloproteinase Inhibitors in Cancer Therapy 2001 Humana New Jersey 223 243
16. For description of assay protocols, see: C.-B. Xue, M.E. Voss, D.J. Nelson, J.J.-W. Duan, R.J. Cherney, I.C. Jacobson, X. He, J. Roderick, L. Chen, R.L. Corbett, L. Wang, D.T. Meyer, K. Kennedy, W.F. DeGrado, K.D. Hardman, C.A. Teleha, B.D. Jaffee, R.-Q. Liu, R.A. Copeland, M.B. Covington, D.D. Christ, J.M. Trzaskos, R.C. Newton, R.L. Magolda, R.R. Wexler, and C.P. Decicco J. Med. Chem. 44 2001 2636
17. J.A. Miller, R.-Q. Liu, G.L. Davis, M.A. Pratta, J.M. Trzaskos, and R.A. Copeland Anal. Biochem. 314 2003 260
18. M. Sawa, H. Kondo, and S. Nishimura Bioorg. Med. Chem. Lett. 12 2002 581
19. 2 conditions
20. 3, DMF (14%)